Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery

Jingjing Yu; Zheng Xu; Wei Yan; Zhenhua Shao

doi:10.1002/ctm2.1576

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (2) : e1576 DOI: 10.1002/ctm2.1576

COMMENTARY

Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery

Jingjing Yu ¹
, Zheng Xu ¹
, Wei Yan ¹^,^†
, Zhenhua Shao ¹^,²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Jingjing Yu, Zheng Xu, Wei Yan, Zhenhua Shao. Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery. Clinical and Translational Medicine, 2024, 14(2): e1576 DOI:10.1002/ctm2.1576

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Curr Pharm Des. 2010;16:488-501.

[2]	Faden J, Citrome L. Schizophrenia: one name, many different manifestations. Med Clin North Am. 2023;107:61-72.

[3]	Yilmaz Z, Zai CC, Hwang R, et al. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res. 2012;140:214-220.

[4]	Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014;19:511-531.

[5]	Moya NA, Yun S, Fleps SW, et al. The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia. Neuropsychopharmacology. 2023;48:690-699.

[6]	Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A. 2001;98:8966-8971.

[7]	Berry MD. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem. 2004;90:257-271.

[8]	Roth BL. Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nat Struct Mol Biol. 2019;26:535-544.

[9]	Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36:41-50.

[10]	Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22.

[11]	Halff EF, Rutigliano G, Garcia-Hidalgo A, Howes OD. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023;46:60-74.

[12]	Ågren R, Betari N, Saarinen M, et al. In vitro comparison of ulotaront (SEP-363856) and ralmitaront (RO6889450): two TAAR1 agonist candidate antipsychotics. Int J Neuropsychopharmacol. 2023;26:599-606.

[13]	Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497-1506.

[14]	Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine. past and present-a pharmacological and clinical perspective. J Psychopharmacol. 2013;27:479-496.

[15]	Liu H, Zheng Y, Wang Y, et al. Recognition of methamphetamine and other amines by trace amine receptor TAAR1. Nature. 2023;624:663-671.

[16]	Shang P, Rong N, Jiang JJ, et al. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Cell. 2023;186:5347-5362. e24.

[17]	Xu Z, Guo L, Yu J, et al. Ligand recognition and G-protein coupling of trace amine receptor TAAR1. Nature. 2023;624:672-681.

[18]	Xiao P, Yan W, Gou L, et al. Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes. Cell. 2021;184:943-956. e918.

[19]	Sitte HH. Structures of the amphetamine-binding receptor will aid drug discovery. Nature. 2023;624:529-530.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.